Inotiv (NASDAQ:NOTV – Get Rating) was downgraded by equities researchers at Jefferies Financial Group from a “buy” rating to a “hold” rating in a research note issued on Thursday, MarketBeat.com reports. They currently have a $8.00 target price on the stock. Jefferies Financial Group’s price objective would suggest a potential upside of 17.30% from the stock’s current price. Jefferies Financial Group also issued estimates for Inotiv’s Q1 2023 earnings at ($0.44) EPS, Q2 2023 earnings at $0.04 EPS, Q3 2023 earnings at $0.29 EPS and Q4 2023 earnings at $0.46 EPS.
A number of other equities research analysts also recently commented on the company. Craig Hallum reduced their target price on Inotiv from $64.00 to $34.00 in a research report on Wednesday, January 11th. Lake Street Capital upgraded Inotiv from a “hold” rating to a “buy” rating and set a $10.00 target price on the stock in a research report on Wednesday, January 11th. Finally, TheStreet downgraded Inotiv from a “c-” rating to a “d+” rating in a research report on Wednesday, November 9th.
Inotiv Trading Up 0.4 %
NASDAQ:NOTV traded up $0.03 on Thursday, reaching $6.82. The company’s stock had a trading volume of 375,194 shares, compared to its average volume of 1,295,536. Inotiv has a 12-month low of $3.64 and a 12-month high of $42.63. The company has a debt-to-equity ratio of 0.92, a current ratio of 1.42 and a quick ratio of 0.98. The stock has a 50 day moving average price of $5.96 and a 200 day moving average price of $14.42.
Institutional Investors Weigh In On Inotiv
Inotiv, Inc operates as a pharmaceutical development company, which engages in the provision of drug discovery, development services, and analytical instruments. The firm operates through the following business segments: Research Services and Research Products. The Research Services segment provides screening and pharmacological testing, preclinical safety testing, formulation development, regulatory compliance, and quality control testing.
- Get a free copy of the StockNews.com research report on Inotiv (NOTV)
- Is The Bottom In For Cyber-Security Stocks?
- Union Pacific, Norfolk Southern Pull into Buying Zone
- Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
- How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?
- Is the Pain Over for Baudax Bio Investors after a 70% Spike?
Receive News & Ratings for Inotiv Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inotiv and related companies with MarketBeat.com's FREE daily email newsletter.